High prevalence of lipopolysaccharide mutants and R2-pyocin susceptible variants in populations sourced from cystic fibrosis lung infections.

Cystic fibrosis (CF) patients often experience chronic, debilitating lung infections caused by antibiotic-resistant , contributing to antimicrobial resistance (AMR). The genetic and phenotypic diversity of populations in CF lungs raises questions about their susceptibility to non-traditional antimicrobials, like bacteriocins. In this study, we focused on R-pyocins, a type of bacteriocin with high potency and a narrow killing spectrum. Our findings indicate that a large number of infectious CF variants are susceptible to R2-pyocins, even within diverse bacterial populations, supporting their potential use as therapeutic agents. The absence of a clear correlation between lipopolysaccharide (LPS) phenotypes and R-pyocin susceptibility suggests that LPS packing density may play a significant role in R-pyocin susceptibility among CF variants. Understanding the relationship between LPS phenotypes and R-pyocin susceptibility is crucial for developing effective treatments for these chronic infections.